---
figid: PMC7425302__fonc-10-01290-g0001
figlink: pmc/articles/PMC7425302/figure/F1/
number: F1
caption: 'Mechanisms of cancer resistance to immunotherapy. Key mechanisms of cancer
  resistance to immunotherapy are briefly described in the figure, including: (I)
  Tumor-intrinsic factors: (i) alteration of antitumor immune response pathways: (1)
  aberrant expression of tumor antigens and changes in immunogenicity (e.g., TAA,
  TSA, antigenic drift, ER stress and autophagy, genes involved in mitochondrial metabolism);
  (2) alterations in the antigen presentation pathways [e.g., proteasome, transporters,
  MHC (loss of HLA expression, β2-M mutations leading to loss of HLA)]; (ii) alteration
  of signaling pathways (e.g., interferon γ and its associated-signaling pathway);
  (iii) forming immunosuppressive microenvironment: (1) secreting inhibitory molecules
  (e.g., exosome PD-L1, PD-L1 variant fragment); (2) functional gene mutations [e.g.,
  Wnt/β-catenin signaling, PTEN/PI3K (phosphatase and tensin homolog/phosphatidylinositol
  3-kinase) signaling, CDK4-CDK6 signaling, MAPK signaling, EGFR, KRAS, STK11, PAK4];
  (3) altering metabolism in TME [e.g., hypoxic, expression of IDO, LXR, CD38/adenosine,
  CD73]; (II) factors of tumor local microenvironment: (i) immunosuppressive cells/molecules:
  immunosuppressive cells [e.g., MDSCs, Tregs, TAM]; activation of coinhibitory receptors
  (e.g., PD-L1, CTLA-4, TIM-3, TIGHT); inhibition of costimulatory receptor (e.g.,
  CD28); (ii) abnormal neovascularization; (III) host-related factors: (i) gender;
  (ii) age; (iii) distribution of body fat; (iv) gut microbiome.'
pmcid: PMC7425302
papertitle: Mechanisms of Cancer Resistance to Immunotherapy.
reftext: Rilan Bai, et al. Front Oncol. 2020;10:1290.
pmc_ranked_result_index: '13511'
pathway_score: 0.8020077
filename: fonc-10-01290-g0001.jpg
figtitle: Cancer resistance to immunotherapy
year: '2020'
organisms:
- Mus musculus
- gut metagenome
- Bacteroides fragilis
- Bacteroides thetaiotaomicron
- Homo sapiens
ndex: ''
annotations: []
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC7425302__fonc-10-01290-g0001.html
  '@type': Dataset
  description: 'Mechanisms of cancer resistance to immunotherapy. Key mechanisms of
    cancer resistance to immunotherapy are briefly described in the figure, including:
    (I) Tumor-intrinsic factors: (i) alteration of antitumor immune response pathways:
    (1) aberrant expression of tumor antigens and changes in immunogenicity (e.g.,
    TAA, TSA, antigenic drift, ER stress and autophagy, genes involved in mitochondrial
    metabolism); (2) alterations in the antigen presentation pathways [e.g., proteasome,
    transporters, MHC (loss of HLA expression, β2-M mutations leading to loss of HLA)];
    (ii) alteration of signaling pathways (e.g., interferon γ and its associated-signaling
    pathway); (iii) forming immunosuppressive microenvironment: (1) secreting inhibitory
    molecules (e.g., exosome PD-L1, PD-L1 variant fragment); (2) functional gene mutations
    [e.g., Wnt/β-catenin signaling, PTEN/PI3K (phosphatase and tensin homolog/phosphatidylinositol
    3-kinase) signaling, CDK4-CDK6 signaling, MAPK signaling, EGFR, KRAS, STK11, PAK4];
    (3) altering metabolism in TME [e.g., hypoxic, expression of IDO, LXR, CD38/adenosine,
    CD73]; (II) factors of tumor local microenvironment: (i) immunosuppressive cells/molecules:
    immunosuppressive cells [e.g., MDSCs, Tregs, TAM]; activation of coinhibitory
    receptors (e.g., PD-L1, CTLA-4, TIM-3, TIGHT); inhibition of costimulatory receptor
    (e.g., CD28); (ii) abnormal neovascularization; (III) host-related factors: (i)
    gender; (ii) age; (iii) distribution of body fat; (iv) gut microbiome.'
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - CD36
  - CD80
  - APC
  - CTLA4
  - PDCD1
  - TRA
  - TRB
  - TRD
  - TRG
  - IFNG
  - B2M
  - CD274
  - IFNGR1
  - HAVCR2
  - TGFB1
  - TGFB2
  - TGFB3
  - CSF1
  - TCR
  - TAM
  - tumor
genes:
- word: fat
  symbol: FAT
  source: hgnc_alias_symbol
  hgnc_symbol: CD36
  entrez: '948'
- word: CD80
  symbol: CD80
  source: hgnc_symbol
  hgnc_symbol: CD80
  entrez: '941'
- word: APC,suchas
  symbol: APC
  source: hgnc_symbol
  hgnc_symbol: APC
  entrez: '324'
- word: APC,
  symbol: APC
  source: hgnc_symbol
  hgnc_symbol: APC
  entrez: '324'
- word: CTLA-4
  symbol: CTLA4
  source: hgnc_symbol
  hgnc_symbol: CTLA4
  entrez: '1493'
- word: PD-1
  symbol: PD-1
  source: hgnc_alias_symbol
  hgnc_symbol: PDCD1
  entrez: '5133'
- word: TCR
  symbol: TCR
  source: bioentities_symbol
  hgnc_symbol: TRA
  entrez: '6955'
- word: TCR
  symbol: TCR
  source: bioentities_symbol
  hgnc_symbol: TRB
  entrez: '6957'
- word: TCR
  symbol: TCR
  source: bioentities_symbol
  hgnc_symbol: TRD
  entrez: '6964'
- word: TCR
  symbol: TCR
  source: bioentities_symbol
  hgnc_symbol: TRG
  entrez: '6965'
- word: IFNY
  symbol: IFNG
  source: hgnc_symbol
  hgnc_symbol: IFNG
  entrez: '3458'
- word: B2M
  symbol: B2M
  source: hgnc_symbol
  hgnc_symbol: B2M
  entrez: '567'
- word: PD-L1
  symbol: PD-L1
  source: hgnc_alias_symbol
  hgnc_symbol: CD274
  entrez: '29126'
- word: IFNYR1/2
  symbol: IFNGR1
  source: hgnc_symbol
  hgnc_symbol: IFNGR1
  entrez: '3459'
- word: TIM-3
  symbol: TIM3
  source: hgnc_alias_symbol
  hgnc_symbol: HAVCR2
  entrez: '84868'
- word: TGF-B
  symbol: TGFB
  source: bioentities_symbol
  hgnc_symbol: TGFB1
  entrez: '7040'
- word: TGF-B
  symbol: TGFB
  source: bioentities_symbol
  hgnc_symbol: TGFB2
  entrez: '7042'
- word: TGF-B
  symbol: TGFB
  source: bioentities_symbol
  hgnc_symbol: TGFB3
  entrez: '7043'
- word: CSF-1
  symbol: CSF1
  source: hgnc_symbol
  hgnc_symbol: CSF1
  entrez: '1435'
- word: TCR
  symbol: TCR
  source: bioentities_symbol
  hgnc_symbol: TRA
  entrez: '6955'
- word: TCR
  symbol: TCR
  source: bioentities_symbol
  hgnc_symbol: TRB
  entrez: '6957'
- word: TCR
  symbol: TCR
  source: bioentities_symbol
  hgnc_symbol: TRD
  entrez: '6964'
- word: TCR
  symbol: TCR
  source: bioentities_symbol
  hgnc_symbol: TRG
  entrez: '6965'
chemicals:
- word: TCR
  source: MESH
  identifier: D017260
- word: TAM
  source: MESH
  identifier: C419191
diseases:
- word: tumor
  source: MESH
  identifier: D009369
figid_alias: PMC7425302__F1
redirect_from: /figures/PMC7425302__F1
figtype: Figure
---
